OTCMKTS:RLMD - Relmada Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $65.80
  • Forecasted Upside: 88.65 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$34.88
▼ -0.01 (-0.03%)
1 month | 3 months | 12 months
Get New Relmada Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RLMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RLMD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$65.80
▲ +88.65% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Relmada Therapeutics in the last 3 months. The average price target is $65.80, with a high forecast of $75.00 and a low forecast of $40.00. The average price target represents a 88.65% upside from the last price of $34.88.
Buy
The current consensus among 5 investment analysts is to buy stock in Relmada Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/31/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/27/2020

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
10/28/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$69.00 ➝ $40.00
i
7/13/2020OppenheimerInitiated CoverageOutperform$75.00
i
5/4/2020SunTrust BanksInitiated CoverageBuy$75.00
i
4/21/2020The Goldman Sachs GroupInitiated CoverageBuy$63.00
i
1/27/2020Jefferies Financial GroupInitiated CoverageBuy$75.00
i
12/16/2019GuggenheimInitiated CoverageBuy$64.00
i
8/25/2016AegisInitiated CoverageBuy
i
5/12/2016FBR & CoReiterated RatingHold
i
Rating by Edward White at FBR & Co
2/16/2016FBR & CoReiterated RatingMarket Perform$6.00
i
(Data available from 11/27/2015 forward)
Relmada Therapeutics logo
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.
Read More

Today's Range

Now: $34.88
$34.00
$35.79

50 Day Range

MA: $34.17
$29.88
$39.09

52 Week Range

Now: $34.88
$23.25
$54.00

Volume

48,670 shs

Average Volume

136,136 shs

Market Capitalization

$566.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A